

Xiao-Dong Jiao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7019754/publications.pdf>

Version: 2024-02-01

19
papers

297
citations

933447

10
h-index

940533

16
g-index

20
all docs

20
docs citations

20
times ranked

446
citing authors

#	ARTICLE	IF	CITATIONS
1	Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial. <i>European Journal of Cancer</i> , 2022, 163, 152-162.	2.8	7
2	Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer. <i>Oncolmmunology</i> , 2021, 10, 1929727.	4.6	32
3	Primary squamous cell carcinoma of pancreas: a population-based study. <i>Gland Surgery</i> , 2021, 10, 1029-1037.	1.1	4
4	Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report. <i>JCO Precision Oncology</i> , 2021, 5, 771-778.	3.0	8
5	<scp> <i>HER2</i> </scp> Splice Site Mutation c.<scp>1899-1G</scp>>A as the Potential Acquired Resistance to Trastuzumab in a Patient with <scp>HER2-Positive</scp> Gastric Adenocarcinoma. <i>Oncologist</i> , 2021, 26, 717-721.	3.7	3
6	Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 3236-3250.	2.8	4
7	Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types. <i>Annals of Translational Medicine</i> , 2020, 8, 860-860.	1.7	9
8	<p>Response to Pyrotinib in a Chinese Patient with Bone-Metastatic Scrotal Pagetâ€™s Disease Harboring Triple Uncommon HER2 Mutation: A Case Report</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6289-6293.	2.0	7
9	The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 147, 102893.	4.4	33
10	<p>MTSS1 inhibits metastatic potential and induces G2/M phase cell cycle arrest in gastric cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5143-5152.	2.0	11
11	Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2019, 14, e115-e117.	1.1	15
12	Basket Trials for Intractable Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 229.	2.8	22
13	The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base. <i>Journal of Thoracic Disease</i> , 2019, 11, 4507-4515.	1.4	27
14	Palbociclib for the Treatment of Metastatic Nasopharyngeal Carcinoma With CDK4 Amplification: A Case Report. <i>JCO Precision Oncology</i> , 2019, 3, 1-4.	3.0	2
15	Primary pulmonary leiomyosarcoma: A population-based study. <i>Lung Cancer</i> , 2018, 116, 67-72.	2.0	28
16	Clinical, pathological and treatment factors associated with the survival of patients with primary pulmonary salivary gland-type tumors. <i>Lung Cancer</i> , 2018, 126, 174-181.	2.0	28
17	Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy. <i>Medical Hypotheses</i> , 2018, 116, 111-113.	1.5	19
18	The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4739-4745.	2.0	23

#	ARTICLE	IF	CITATIONS
19	Adenosquamous carcinoma of the bile duct: a population-based study. Cancer Management and Research, 2018, Volume 10, 439-446.	1.9	15